Asia Pacific Vitrification Market Size, Share & Industry Trends Analysis Report By Specimen (Oocytes (Devices, Kits & Consumables), Embryo (Devices, Kits & Consumables), and Sperm), By End-use, By Country and Growth Forecast, 2023 - 2030

The Asia Pacific Vitrification Market would witness market growth of 18.1% CAGR during the forecast period (2023-2030).

The vital role assisted reproductive technologies play in vitrification is one of the main drivers of the market's rise. The cryopreservation of embryos, oocytes, and sperm has been transformed by vitrification in fertility preservation, greatly enhancing the success rates of in-vitro fertilization (IVF) procedures. Viable embryos are more likely to develop throughout IVF cycles because of vitrification, which guarantees quick chilling and thawing while reducing cellular damage.

Furthermore, vitrification is now widely used in the pharmaceutical and biotechnology sectors to store biological samples, vaccines, and pharmaceuticals for extended periods. The potency and effectiveness of these life-saving drugs have proven to be significantly enhanced by vitrification's capacity to protect the integrity and stability of sensitive biomolecules. The need for vitrification techniques to preserve tissues, stem cells, and organs for potential future treatments has also increased due to cellular and regenerative medicine developments.

Japan is a nation with one of the world's oldest populations, and its birth rate has been falling for many years. The Japanese government has recently made a lot of effort to provide national coverage for treatment for infertility by covering a sizable portion of the cost of IVF for up to six rounds. These advantageous elements are anticipated to assist the expansion of the market in the APAC region.

The China market dominated the Asia Pacific Vitrification Market, By Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $1,683.7 million by 2030. The Japan market is registering a CAGR of 17.4% during (2023 - 2030). Additionally, The India market would showcase a CAGR of 18.8% during (2023 - 2030).

Based on Specimen, the market is segmented into Oocytes (Devices, Kits & Consumables), Embryo (Devices, Kits & Consumables), and Sperm. Based on End-use, the market is segmented into IVF Clinics, and Biobanks. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Vitrolife AB, Genea Limited (Liverpool Partners Group), NidaCon International AB, Minitüb GmbH, Cryo Bio System (IMV Technologies Group), CooperSurgical Fertility & Genomic Solutions (The Cooper Companies, Inc.), FUJIFILM Irvine Scientific, Inc. (Fujifilm Holdings Corporation), Biotech, Inc., Kitazato Corporation and Shenzhen VitaVitro Biotech

Scope of the Study

Market Segments Covered in the Report:

By Specimen

• Oocytes
• Devices
• Kits & Consumables
• Embryo
• Devices
• Kits & Consumables
• Sperm

By End-use

• IVF Clinics
• Biobanks

By Country

• China
• Japan
• India
• South Korea
• Singapore
• Malaysia
• Rest of Asia Pacific

Key Market Players

List of Companies Profiled in the Report:

• Vitrolife AB
• Genea Limited (Liverpool Partners Group)
• NidaCon International AB
• Minitüb GmbH
• Cryo Bio System (IMV Technologies Group)
• CooperSurgical Fertility & Genomic Solutions (The Cooper Companies, Inc.)
• FUJIFILM Irvine Scientific, Inc. (Fujifilm Holdings Corporation)
• Biotech, Inc.
• Kitazato Corporation
• Shenzhen VitaVitro Biotech

Unique Offerings

• Exhaustive coverage
• The highest number of Market tables and figures
• Subscription-based model available
• Guaranteed best price
• Assured post sales research support with 10% customization free